Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Clonal composition of karyotypically normal AML at diagnosis is not affected by the microenvironment

Monika M. Toma, Adam Karami, Margaret Nieborowska-Skorska, Tomasz Skorski

Blood Neoplasia (2025) 2 (2): 100073.

https://doi.org/10.1016/j.bneo.2025.100073

Published: 2025

Journal Articles

New leads to enhance tagraxofusp efficacy in pDC-AML

Morgane Boichut, Margaux Poussard, Xavier Roussel, Imane Belakri, Sabeha Biichlé, Maxime Fredon, Florian Renosi, Romain Boidot, Olivier Adotevi, Christopher Brooks, Francine Garnache-Ottou, Fanny Angelot Delettre

Blood Neoplasia (2025) 2 (2): 100066.

https://doi.org/10.1016/j.bneo.2025.100066

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma

Blood Neoplasia (2025) 2 (2): 100072.

https://doi.org/10.1016/j.bneo.2025.100072

Published: 2025

Includes: Supplemental data

Journal Articles

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes

Blood Neoplasia (2025) 2 (2): 100068.

https://doi.org/10.1016/j.bneo.2025.100068

Published: 2025

Includes: Supplemental data

Journal Articles

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms

Astrid G. S. van Halteren, Paul G. Kemps, Jelske Forma-Borst, Yanling Xiao, Maud A. J. I. van den Oetelaar, Nina U. Gelineau, Robert M. Verdijk, Lydia E. Vos, Koen D. Quint, Cor van den Bos, Eli L. Diamond, Jan A. M. van Laar

Blood Neoplasia (2025) 2 (2): 100074.

https://doi.org/10.1016/j.bneo.2025.100074

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

Zhuoer Xie, Najla Al Ali, Ling Zhang, Peter Papenhausen, Virginia Olivia Volpe, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Alison Walker, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood Neoplasia (2025) 2 (2): 100062.

https://doi.org/10.1016/j.bneo.2024.100062

Published: 2025

Includes: Supplemental data

Journal Articles

A feedforward loop between ACLY and MYC supports T-ALL progression in vivo

Victoria da Silva-Diz, Amartya Singh, Maya Aleksandrova, Oekyung Kim, Christopher Thai, Olga Lancho, Patricia Renck Nunes, Hayley Affronti, Alexia Martínez de Paz, Steven Z. Josefowicz, Xiaoyang Su, Kathryn E. Wellen, Daniel Herranz

Blood Neoplasia (2025) 2 (2): 100069.

https://doi.org/10.1016/j.bneo.2025.100069

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

Patricia L. Kropf, Woonbok Chung, Raji Shameem, Lianchun Xiao, Curt Balch, Xuelin Huang, Jean-Pierre J. Issa

Blood Neoplasia (2025) 2 (2): 100071.

https://doi.org/10.1016/j.bneo.2025.100071

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood Neoplasia (2025) 2 (2): 100082.

https://doi.org/10.1016/j.bneo.2025.100082

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601

Takahiro Nakashima, Tomotaka Suzuki, Ryunosuke Machida, Kazuyuki Shimada, Tsutomu Kobayashi, Dai Maruyama, Wataru Munakata, Shinsuke Iida, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Hirokazu Nagai

Blood Neoplasia (2025) 2 (2): 100077.

https://doi.org/10.1016/j.bneo.2025.100077

Published: 2025

Includes: Supplemental data

Journal Articles

Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United States

Ming S. Lee, Rebecca E. Kaiser, Christopher D. Armstrong, David B. Dukenik, Nancy S. Elliott, Raymond R. Balise, Justin M. Watts, Mikkael A. Sekeres, Erin N. Kobetz, Justin Taylor

Blood Neoplasia (2025) 2 (2): 100078.

https://doi.org/10.1016/j.bneo.2025.100078

Published: 2025

Journal Articles

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study

Blood Neoplasia (2025) 2 (2): 100075.

https://doi.org/10.1016/j.bneo.2025.100075

Published: 2025

Journal Articles

A novel 3-way translocation involving ETV6 :: IL3 drives AML with eosinophilia

Blood Neoplasia (2025) 2 (2): 100079.

https://doi.org/10.1016/j.bneo.2025.100079

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell sequencing reveals shared clonal signatures in nonmalignant B and tumor cells in T-prolymphocytic leukemia

Caroline Hesselager, Ingrid Thörn, Millaray Marincevic, Claes Ladenvall, Jonas Almlöf, Sara Löfgren, Simone Weström, Helena Nord, Lesley-Ann Sutton, Lucia Cavelier, Panagiotis Baliakas, Rose-Marie Amini

Blood Neoplasia (2025) 2 (2): 100076.

https://doi.org/10.1016/j.bneo.2025.100076

Published: 2025

Includes: Supplemental data

Journal Articles

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN

Naveen Pemmaraju, Luan Hai Phan, Geoffrey Fell, Marlise R. Luskin, Mahesh Swaminathan, Sherry Pierce, Courtney DiNardo, Abhishek Maiti, Marina Konopleva, Andrew A. Lane

Blood Neoplasia (2025) 2 (2): 100086.

https://doi.org/10.1016/j.bneo.2025.100086

Published: 2025

Journal Articles

Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis

Dai Chihara, Shibing Yang, Savreet Bains Chawla, Guihua Zhang, Anthony Wang, Junhua Yu, Donald Arnette, Fernando Rivas Navarro, Julie Blaedel, Alex Mutebi

Blood Neoplasia (2025) 2 (2): 100080.

https://doi.org/10.1016/j.bneo.2025.100080

Published: 2025

Includes: Supplemental data

Journal Articles

Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis

Nathalie Loeb, Olivia Katsnelson, Anshika Jain, Parsa Tahvildar, Daniel Teitelbaum, Alejandro Garcia-Horton

Blood Neoplasia (2025) 2 (2): 100070.

https://doi.org/10.1016/j.bneo.2025.100070

Published: 2025

Includes: Supplemental data

Journal Articles

Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis

Blood Neoplasia (2025) 2 (2): 100092.

https://doi.org/10.1016/j.bneo.2025.100092

Published: 2025

Includes: Supplemental data

Journal Articles

Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance

Matthew R. M. Jotte, Angela Stoddart, Tanner C. Martinez, Raven Moten, Yuqing Xue, Molly K. Imgruet, Hunter Blaylock, Henna S. Nam, Bonnie Hu, Jermaine Austin, Ningfei An, Saira Khan, Sandeep K. Gurbuxani, Megan E. McNerney

Blood Neoplasia (2025) 2 (2): 100083.

https://doi.org/10.1016/j.bneo.2025.100083

Published: 2025

Includes: Supplemental data

Journal Articles

Checkpoint immunotherapy is associated with preferential activation of tumor-antigen specific CD4 + T cells in MDS.

Elizabeth A. Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi, Laura W. Dillon, Devdeep Mukherjee, Christopher S. Hourigan, Jacqueline Peng, Shovik Bandyopadhyay, Kai Tan, Kristopher M. Attwood, Joseph B. Kuechle, Prashant K. Singh, Jianmin Wang, Michael J. Nemeth

Blood Neoplasia 100106.

https://doi.org/10.1016/j.bneo.2025.100106

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Clonal composition of karyotypically normal AML at diagnosis is not affected by the microenvironment

New leads to enhance tagraxofusp efficacy in pDC-AML

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

A feedforward loop between ACLY and MYC supports T-ALL progression in vivo

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601

Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United States

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study

A novel 3-way translocation involving ETV6 :: IL3 drives AML with eosinophilia

Single-cell sequencing reveals shared clonal signatures in nonmalignant B and tumor cells in T-prolymphocytic leukemia

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN

Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis

Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis

Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis

Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance

Checkpoint immunotherapy is associated with preferential activation of tumor-antigen specific CD4 + T cells in MDS.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only